Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: real world evidence from the Nordic EMPRISE study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36097728/
doi: 10.1111/dom.14870. Online ahead of print. Collaborators, Affiliations 1 Department of clinical science and education Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. 2 Quantify Research, Stockholm, Sweden. 3 Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. 4 TFS HealthScience, Barcelona, Spain. 5 Boehringer Ingelheim AB, Stockholm, Sweden. 6 Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.
Conclusions: Empagliflozin treatment compared to DPP-4i reduced cardiorenal events and overall mortality, which may explain lower HCRU among empagliflozin users in Sweden.